H
H. Shabtai
Researcher at Tel Aviv Sourasky Medical Center
Publications - 14
Citations - 1659
H. Shabtai is an academic researcher from Tel Aviv Sourasky Medical Center. The author has contributed to research in topics: Effects of sleep deprivation on cognitive performance & Rivastigmine. The author has an hindex of 11, co-authored 14 publications receiving 1479 citations.
Papers
More filters
Journal ArticleDOI
Construction of freezing of gait questionnaire for patients with Parkinsonism.
TL;DR: The FOG questionnaire that was constructed is highly reliable in assessing freezing of gait, unrelated to falls, in patients with PD.
Journal ArticleDOI
Subjective memory complaints in elders: depression, anxiety, or cognitive decline?
Yacov Balash,M. Mordechovich,H. Shabtai,Nir Giladi,Nir Giladi,Tanya Gurevich,Tanya Gurevich,Amos D. Korczyn,Amos D. Korczyn +8 more
TL;DR: To study the association of subjective memory complaints (SMC) with affective state and cognitive performance in elders, a large number of elders were surveyed and it was found that the number of complaints was higher in elders with a negative affect than in those with a positive one.
Journal ArticleDOI
Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis.
TL;DR: Clozapine and quetiapine are effective atypical neuroleptics for the treatment of psychotic symptoms in PD, but its use is associated with an increased risk of leukopenia.
Journal ArticleDOI
Gait festination in Parkinson's disease.
TL;DR: Festinating gait festination was clearly associated with longer duration of PD symptoms but not with disease severity as reflected in the motor part of the Unified Parkinson's Disease Rating Scale (UPDRS).
Journal ArticleDOI
Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson's disease.
TL;DR: This study suggests the existence of “endogenic” factors as substantial contributors in the genesis of PD hallucinations and suggests the clinical implications may be earlier administration of antipsychotic treatment and not as traditionally accepted, dose reduction of antiparkinsonian drugs.